Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025

H.R. 9260 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027), Title II, regarding funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill S.4283 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2026)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Graduate Medical Education (GME): -"Resident Physician Shortage Reduction Act of 2025" (H.R. 4731) which would increase GME positions in rural areas; -the "Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025" (H.R. 4445) FDA Modernization: -Modeling non-animal studies for medtech -Biotechnology: reduce regulatory barriers; align public-private investment -Medical Device Electronic Labeling Act (IFU) bill (FDA issue) (H.R. 1539) FDA Reform: -Medical device shortage reporting; domestic production of medical products; use of real-world data (RWD) and real-world evidence (RWE) Nursing Workforce Shortage Artificial Intelligence (AI): -Presidential E.O. 14179 setting forth national policy framework for AI and Congressional action to provide preemption of conflicting state requirements, safe and efficient adoption of AI. Right-to-Repair provision in House NDAA H.R.4784/H.R. 8800 broadly would impact FDA regulated medical devices

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352 119th Congress) Senate PASTEUR Act not yet introduced in 119th Congress, Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445)not yet introduced in Senate, SUPERBUGS Act, H.R.7879, 119th Congress.

Client expense: $169,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, reintroduction of the PASTEUR Act, CMS practice expense final rule, draft legislation to carve out ID physicians from CMS practice expense final rule, ioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352, not yet introduced in the Senate, upcoming legislation on CMS practice expense cuts.

Client expense: $169,000 · Firm income: Not reported

Graduate Medical Education (GME): -"Resident Physician Shortage Reduction Act of 2025" (H.R. 4731) which would increase GME positions in rural areas; -the "Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025" (H.R. 4445) FDA Modernization: -Modeling non-animal studies for medtech -Biotechnology: reduce regulatory barriers; align public-private investment -Medical Device Electronic Labeling Act (IFU) bill (FDA issue) (H.R. 1539) FDA Reform: -Medical device shortage reporting; domestic production of medical products; use of real-world data (RWD) and real-world evidence (RWE) Nursing Workforce Shortage Artificial Intelligence (AI): -Presidential E.O. 14179 setting forth national policy framework for AI and Congressional action to provide preemption of conflicting state requirements, safe and efficient adoption of AI.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026), Title II, regarding funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill H.R.7148 (Consolidated Appropriations Act, 2026), Division B, Title II, regarding funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally Fiscal Year 2027 funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally

Client expense: Not reported · Firm income: $50,000

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (H.R. 4445), Monkeypox outbreak and response (generally, no specific information), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, reintroduction of the PASTEUR Act, CMS practice expense final rule, draft legislation to carve out ID physicians from CMS practice expense final rule

Client expense: $68,000 · Firm income: Not reported

H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026), Title II, regarding funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally H.R. 5371 (Continuing Appropriations and Extensions Act, 2026), entire bill H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill

Client expense: Not reported · Firm income: $50,000

Rural Health Transformation Program included in One Big Beautiful Bill Act (H.R. 1) H.R. 4725/S. 2462 - Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act of 2025 S. 2532 - Safe Response Act S. 2540 - Comprehensive Addiction and Recovery Justice Grant Reauthorization Act of 2025 S. 1941 - Cure Hepatitis C Act of 2025 H.R. 4445 - Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025

Client expense: $46,531 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1 (One Big Beautiful Bill Act), regarding funding for infectious diseases programs generally H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026), Title II, regarding funding for workforce programs, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally H.R. 5371 (Continuing Appropriations and Extensions Act, 2026), entire bill H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill

Client expense: Not reported · Firm income: $50,000

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (H.R. 4445), Monkeypox outbreak and response (generally, no specific information), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues.

Client expense: $300,000 · Firm income: Not reported

Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR);Verifying Accurate Leading Edge IVCT Development (VALID Act HR 3128/S.2209), Infectious diseases and bio-preparedness health professionals loan repayment issues, BIO Preparedness Workforce Act (S.3244/H.R.5602), Monkeypox outbreak and response (generally, no specific information), ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation

Client expense: $285,000 · Firm income: Not reported